Thomas E Serena
President, Serena Groups | USA
Title: Translational medicine in wound healing: The future is bright
Biography: Thomas E Serena
Clinical research is an essential component of SerenaGroup’s ™ Center-of-Excellence model for wound and hyperbaric centers. We are one of the world’s leaders in clinical research on wound care and hyperbaric medicine, having conducted over 100 clinical trials involving growth factors, gene therapy, genomics, Cellular and Tissue Based products, and novel pharmaceuticals. In 2011 SerenaGroup™ clinics conducted the research that led to the first diagnostic in wound care; this diagnostic procedure was identified in the ensuing manuscript as the Serena Technique©. In conjunction with Harvard’s Wellman Institute we developed and performed the initial clinical studies on a painless, bedside epidermal skin-harvesting device that is functioning not only in hospitals in the US but in third-world clinics as well. We have filed numerous patents on novel products that were conceived in the clinics facing unmet needs, developed in our lab and returned to the clinic for clinical trials. Our emphasis on clinical research over the years has drawn a group of young clinicians and scientists who are dedicated to advancing the science of wound healing to participate in our research projects in the US and internationally. We formed the nation’s first wound healing cooperative group consisting of more than 30 centers in the US and worldwide that now conducts entire multi-national clinical trials. In 2015 SerenaGroup Innovation™ opened a laboratory at Northeastern Ohio Medical School to conduct preclinical studies in wound healing. As a result of these efforts, our research team has filed numerous patents. Serena will review innovations in the field of wound care including therapies on the horizon, such as genomics and genetically modified products. He will review data from ongoing trials on indocyanine green fluorescent angiography and cellular-and-tissue-based products for wound care(CTP), examine advances in hyperbaric oxygen therapy, diagnostics and prognostics in wound care, present new pharmaceuticals on the horizon, and discuss the impact of quality measures on practice and reimbursement.